Dr. Kristina Zakhary to Teach Advanced Facelift & Brow Lift Cadaver Dissection Course at Marina Medical's Pre-Conference Lab in Miami
This hands-on cadaver workshop is designed for surgeons seeking to refine and expand their expertise in two highly effective, proven facial rejuvenation techniques. Dr. Zakhary, alongside distinguished faculty Dr. Nabil Fanous and Dr. Jeffrey Spiegel, will provide step-by-step instruction on advanced facelift and brow lift procedures, emphasizing safety, efficiency, and natural-looking results.
'Surgeons learn best through immersive, hands-on experience,' said Dr. Zakhary. 'This course allows participants to deepen their understanding of anatomy while mastering techniques that provide durable, natural, and aesthetically harmonious outcomes.'
The 'Optimum Mobility' Facelift technique focuses on mobilizing facial tissue to achieve natural results with reduced recovery time, while the '003' Brow Lift is designed to rejuvenate the upper face with precision and minimal scarring. Attendees will benefit from close mentorship, live demonstrations, and individual guidance throughout the dissection process.
As the current President of the Canadian Academy of Facial Plastic and Reconstructive Surgery (CAFPRS) and with over 20 years of dedicated practice in facial plastic surgery, Dr. Zakhary brings a wealth of experience, technical skill, and teaching expertise to this international training event.
Event Details:
Location: Loews Hotel, Miami, Florida
Host: Marina Medical / Pre-Conference for Global Aesthetics Conference 2025
For more information and registration, visit http://www.bytm.org and also @drfacialplastics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
New Research from Humana Finds Value-Based Care Delivers Higher Quality of Care for Heart Failure Patients
LOUISVILLE, Ky.--(BUSINESS WIRE)--Value-based care delivers a higher quality of care and better medication prescription adherence to evidence-based medicine for Medicare Advantage patients diagnosed with heart failure, according to findings released today by leading health and well-being company Humana Inc. (NYSE: HUM) in its latest Value-Based Care Issue Brief. Heart failure continues to affect a growing number of Americans, with 11.4 million expected to be diagnosed by 2050. Patients with heart failure experience a higher likelihood of hospitalizations and visit the emergency department twice as often. The guideline-directed medical therapy is quadruple therapy, however, less than one in five patients hospitalized with heart failure with HFrEF receive this therapy within six months of discharge. Data analyzed in Humana's Value-Based Care Issue Brief compares patients diagnosed with heart failure with reduced ejection fraction (HFrEF) after a hospitalization who receive care from value-based clinicians and those who do not. Patients treated by value-based care clinicians were nearly 28% more likely to receive full quadruple therapy, the gold standard evidence-based medical treatment. 'Coordinated care impacts the quality of care, particularly for seniors post-hospitalization. A care team who holistically sees a patient's needs and relies on their collective expertise to provide the highest quality of care is the value-based care model,' said Dr. Kate Goodrich, Chief Medical Officer at Humana. 'Value-based care depends on primary care physicians (PCP), specialists, care teams, and patients working together to achieve better health outcomes.' Humana's newest Value-Based Care Issue Brief reinforces that the value-based care model is the meaningful difference for patients with heart failure with HFrEF. Those receiving care from value-based primary care clinicians experienced better medical management. Clinicians under value-based care deliver proactive care and are incentivized to provide high-value interventions. The traditional fee-for-service model is a fragmented experience for clinicians and patients with no incentives to reduce low-value care. In addition, patients aligned with value-based care practices better manage chronic diseases, according to Humana's Value-Based Care Report. These findings affirm more than a decade of Humana's research advancing value-based care that concludes patients aligned with value-based care see their primary care physician more often, are more satisfied with the quality of care, and have better management of chronic diseases. 'Our commitment to furthering value-based care continues to accelerate for patients, primary care clinicians, and specialists. The health outcomes for patients continue to be clear,' said Goodrich. 'A smarter, more coordinated healthcare experience is necessary for patient-centered care.' Read Humana's Value-Based Care Issue Brief in full here or visit About Humana Humana Inc. (NYSE: HUM) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at and at
Business Wire
2 hours ago
- Business Wire
Healthfirst Ranked #1 in Quality Among New York State Medicaid Plans
NEW YORK--(BUSINESS WIRE)--Healthfirst, a leading not-for-profit health plan serving more than two million New Yorkers, has been recognized as the top-performing Medicaid Managed Care plan in New York State's Department of Health Medicaid Quality Incentive Program results for 2023, which were released in August 2025. Out of 12 participating plans statewide, Healthfirst achieved the highest rating for quality of care, underscoring its effectiveness in delivering access to coordinated, community-based care through its extensive provider network. For the past three years, Healthfirst has achieved tier one performance in the annual Medicaid Quality Incentive Program results and in 2023 received the highest ranking among all plans. Share For the past three years, Healthfirst has achieved tier one performance in the annual Medicaid Quality Incentive Program results and in 2023 received the highest ranking among all plans. Key drivers in the 2023 measurement year results include behavioral health programming designed to meet members' needs, as well as ongoing efforts to enhance member experience. In addition, Healthfirst members rated our health plan above the statewide average in New York's Medicaid Adult member satisfaction survey. 'Healthfirst's number one ranking reflects how we are delivering on our not-for-profit mission in partnership with our provider network of top-notch medical centers, doctors, and community physicians who are integral to our communities,' said Pat Wang, President and CEO of Healthfirst. 'For more than 30 years, Healthfirst has earned the trust of members by putting their needs first and making health insurance easier to understand – grounded in our belief that all New Yorkers deserve the highest-quality care.' The New York State Medicaid Quality Incentive Program evaluates health plans based on nationally recognized quality measures and health outcomes. These measures include preventive care; management of chronic conditions such as diabetes, asthma, and cancer; maternity and postpartum care; behavioral health; and developmental screenings for children and adolescents. A plan's performance in the program indicates the quality of care provided to its members relative to all plans in the Medicaid Managed Care market. The program uses multiple data sources to determine results, including: 2023 Healthcare Effectiveness Data and Information Set (HEDIS) and Quality Assurance Reporting Requirements (QARR) data (measurement year 2023); The most recent Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey for Medicaid (administered in fall 2023 with results released in May 2024); and Regulatory compliance information from 2022 and 2023. About Healthfirst Healthfirst believes that every New Yorker deserves access to the best available healthcare. As one of New York's highest-quality health insurers, we make this a reality for more than two million members. Founded more than 30 years ago by the leading hospital systems in downstate New York, Healthfirst established a partnership model that enables hospitals, health systems, and physicians in our network to prioritize health outcomes over profits, placing the needs of our members and community first. Healthfirst serves members in New York City, on Long Island, and in Westchester, Rockland, Sullivan, and Orange counties, offering market-leading products to suit every life stage. Our offerings include Medicaid plans, Medicare Advantage plans, Child Health Plus plans, Essential Plans, Long-Term Care plans, and Qualified Health plans. For more information on Healthfirst, please visit
Business Wire
2 hours ago
- Business Wire
Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that company management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 A.M. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of the company's website at A replay will be available for 30 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
